Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 11, pp 3745–3755 | Cite as

Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis

  • Yibo Fan
  • Xiaofang Che
  • Jinglei Qu
  • Kezuo Hou
  • Ti Wen
  • Zhi Li
  • Ce Li
  • Shuo Wang
  • Ling Xu
  • Yunpeng LiuEmail author
  • Xiujuan QuEmail author
Translational Research and Biomarkers
  • 280 Downloads

Abstract

Background

A recent study showed that circulating exosomal PD-L1 is an effective predictor for anti-PD-1 therapy in melanomas. Exosomal PD-L1 induced immunosuppression microenvironments in cancer patients. However, its prognostic value and immunosuppressive effect in gastric cancer (GC) were poorly understood.

Methods

We retrospectively evaluated the prognostic value of exosomal PD-L1 and soluble PD-L1 in preoperative plasma of 69 GC patients. The correlation between exosomal PD-L1 and the T cell counts or cytokine in the plasma was evaluated in 31 metastatic GC patients before chemotherapy.

Results

Overall survival (OS) was significantly lower in the high exosomal PD-L1 group compared with the low exosomal PD-L1 group (P = 0.004). Exosomal PD-L1 was an independent prognostic factor in GC (n = 69, 95% confidence interval = 1.142–7.669, P = 0.026). However, soluble PD-L1 showed no correlation with OS (P = 0.139). Additionally, exosomal PD-L1 in the plasma samples of 31 metastatic GC patients was negatively associated with CD4+ T cell count (P = 0.001, R = − 0.549), CD8+ T-cell count (P = 0.054, R = − 0.349), and granzyme B (P = 0.002, R = − 0.537), indicating that exosomal PD-L1 was associated with immunosuppressive status of GC patients. GC cells also secreted exosomal PD-L1 and were positively associated with the amount of PD-L1 in corresponding GC cell lines. Besides, exosomal PD-L1 significantly decreased T-cell surface CD69 and PD-1 expressions compared with soluble PD-L1 due to its stable and MHC-I expression.

Conclusions

Overall, exosomal PD-L1 predicts the worse survival and reflects the immune status in GC patients, resulting from a stronger T-cell dysfunction due to its stable and MHC-I expression.

Notes

Funding

The National Key Research and Development Program of China (No. 2017YFC1308900). National Natural Science Foundation of China (Nos. 81372546, 81602098, 81673025, 31770963), Science and Technology Plan Project of Liaoning Province (Nos. 2014225013, 2014226033, 2016007010), the general project of Liaoning Province Department of Education (No. LZ2014037), Distinguished professor of Liaoning Province, Project for clinical ability construction of Chinese medicine.

Disclosure

The authors declare no conflicts of interests.

Ethics approval and Consent to Participate

This study was approved by the Human Ethics Review Committee of the First Hospital of China Medical University. All patients agree to participate in our study.

Consent for Publication

The authors certify that no portion of this manuscript has been previously published. Authors listed have approved to submit this manuscript to the journal.

References

  1. 1.
    Eto S, Yoshikawa K, Nishi M, et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer. 2016;19(2):466–71.CrossRefPubMedGoogle Scholar
  2. 2.
    Xu C, Fillmore CM, Koyama S, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinomawith elevated PD-L1 expression. Cancer Cell. 2014;25(5):590–604.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–95.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. 2015;37(4):764–82.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Raufi AG, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol. 2015;6(5):561–9.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Joshi SS, Maron SB, Catenacci DV. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Future Oncol. 2018;14:417–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Kim JW, Nam KH, Ahn SH, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer. 2016; 19(1):42–52.CrossRefGoogle Scholar
  8. 8.
    Qing Y, Li Q, Ren T, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 2015;9:901–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hou J, Yu Z, Xiang R, et al. Correlation between infiltration of FOXP3 + regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol. 2014;96(3):284–91.CrossRefPubMedGoogle Scholar
  10. 10.
    Frigola X, Inman BA, Lohse CM, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011;17(7):1915–23.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kshirsagar SK, Alam SM, Jasti S, et al. Immunomodulatory molecules are released from the first trimester and term placenta via exosomes. Placenta. 2012;33(12):982–90.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ruffner MA, Kim SH, Bianco NR, Francisco LM, Sharpe AH, Robbins PD. B7-1/2, but not PD-L1/2 molecules, are required on IL-10-treated tolerogenic DC and DC-derived exosomes for in vivo function. Eur J Immunol. 2009;39(11):3084–90.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Stenqvist AC, Nagaeva O, Baranov V, Mincheva-Nilsson L. Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus. J Immunol. 2013; 191(11):5515–23.CrossRefPubMedGoogle Scholar
  14. 14.
    Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl). 2013;91(4):431–7.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Cai Z, Zhang W, Yang F, et al. Immunosuppressive exosomes from TGF-β1 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells. Cell Res. 2012;22(3):607–10.CrossRefPubMedGoogle Scholar
  16. 16.
    Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yang Y, Li CW, Chan LC, et al. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018;28(8):862–4.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Theodoraki MN, Yerneni S, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 2018;24:896–905.CrossRefPubMedGoogle Scholar
  19. 19.
    Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–82.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Qu JL, Qu XJ, Zhao MF, et al. The role of cbl family of ubiquitin ligases in gastric cancer exosome-induced apoptosis of Jurkat T cells. Acta Oncol. 2009;48(8):1173–80.CrossRefGoogle Scholar
  21. 21.
    Zhang LY, Qu XJ, Fan YB, et al. The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastas. Oncotarget. 2015;6(26):22918–33.PubMedPubMedCentralGoogle Scholar
  22. 22.
    An T, Qin S, Xu Y, et al. Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. J Extracell Vesicles. 2015;4:27522.CrossRefPubMedGoogle Scholar
  23. 23.
    Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn. 2015: S1525-1578(15)00047-1.Google Scholar
  24. 24.
    Wang L, Wang H, Chen H, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. 2015;6(38):41228–36.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Zheng Z, Bu Z, Liu X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res. 2014;26(1):104–11.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Johnson DB, Estrada MV, Salgado R, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Zhang X, Pei Z, Chen J, et al. Exosomes for immunoregulation and therapeutic intervention in cancer. J Cancer. 2016;7(9):1081–7.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Filipazzi P, Bürdek M, Villa A, Rivoltini L, Huber V. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol. 2012;22(4):342–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30(6):836–48.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Whiteside TL. Tumor-derived exosomes and their role in cancer progression. Adv Clin Chem. 2016;74:103–41.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Yibo Fan
    • 1
    • 2
  • Xiaofang Che
    • 1
    • 2
  • Jinglei Qu
    • 1
    • 2
  • Kezuo Hou
    • 1
    • 2
  • Ti Wen
    • 1
    • 2
  • Zhi Li
    • 1
    • 2
  • Ce Li
    • 1
    • 2
  • Shuo Wang
    • 1
    • 2
  • Ling Xu
    • 1
    • 2
  • Yunpeng Liu
    • 1
    • 2
    Email author
  • Xiujuan Qu
    • 1
    • 2
    Email author
  1. 1.Department of Medical OncologyThe First Hospital of China Medical UniversityShenyangChina
  2. 2.Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning ProvinceThe First Hospital of China Medical UniversityShenyangChina

Personalised recommendations